



DUPILUMAB PROVIDES ACCEPTABLE SAFETY AND SUSTAINED EFFICACY FOR UP TO 4 YEARS IN AN OPEN-LABEL STUDY OF ADULTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS

Lisa A. Beck · Mette Deleuran · Robert Bissonnette · Marjolein de Bruin-Weller ·
Ryszard Galus · Takeshi Nakahara · Seong Jun Seo · Faisal A. Khokhar · Jignesh Vakil ·
Jing Xiao · Ainara Rodriguez Marco · Noah A. Levit · John T. O'Malley · Arsalan Shabbir

American Journal of Clinical Dermatology

DUPILUMAB OPEN-LABEL STUDY UP TO 4 YEARS

Including patients who switched to biweekly dosing



SAFETY

The safety profile of dupilumab was acceptable and consistent with previously reported data. Most treatment-emergent adverse events (TEAEs) were of mild-to-moderate severity





These included nasopharyngitis, atopic dermatitis, upper respiratory tract infection, oral herpes, conjunctivitis, injection-site reaction, and headache

EFFICACY


Mean percent improvement in EASI and Pruritus NRS from baseline of parent study to Week 204



EFFICACY AFTER DOSING SWITCH



COMPLIANCE



DUPILUMAB TREATMENT UP TO 4 YEARS



- Well tolerated and acceptable safety profile
- Efficacy maintained throughout and during switch to approved q2w dose
- Supports long-term, continuous use of dupilumab

